P-072 - Overall survival (OS) of patients with advanced gastric cancer (AGC) according to the availability of 5-FU, platinum, taxanes and irinotecan as firs...

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Gastric Cancer
Presenter M.J. Kim
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M.J. Kim1, J. Lee1, S.H. Park2, K.H. Yoo1, S.J. Lee1, S. Kim3
  • 1Myoung-ji Hospital, Goyang/KR
  • 2Sungkyunkwan University School of Medicine, Seoul/KR
  • 3Korea University, Seoul/



Patients with AGC can be eligible for multiple lines of chemotherapy. Although several randomized trials have demonstrated the benefit of second-line chemotherapy compared with best supportive care, there is no evidence that further lines of chemotherapy will result in substantial prolongation of OS.


This combined, retrospective analysis compared OS of patients who were treated with first-line capecitabine and cisplatin (XP)-based chemotherapy. Case report forms obtained from AGC patients enrolled in two randomized clinical trials were reviewed and analyzed: (1) XP with or without epirubicin (n = 91), (2) XP with or without simvastatin (n = 244). Individual patients' OS data were compared according to the availability of first-line chemotherapy, taxanes or irinotecan given as second- or third-line therapy.


Among 335 patients who were treated with first-line XP-based chemotherapy, 229 (68%) received second-line therapy with taxanes or irinotecan. Third-line chemotherapy was given to 100 patients. When grouped on the availability of first, second and third-line chemotherapy, baseline patient characteristics showed no significant differences. The median OS for patients who had access to first, second and third-line chemotherapy were 8.9, 12.7 and 15.2 months, respectively, showing a significant correlation with the percentage of those receiving second and third-line chemotherapy (P < 0.001).


Similar to a model developed in colorectal cancer, we found clear OS differences between AGC patients who were treated with one, two, or three chemotherapy regimens.